GKOS

NEUTRALProduct

Glaukos Corporation

2026-09-08

Price

$185.04

+3.07%

This is the 2026-09-08 snapshot — the signals and analysis for GKOS as of this single trading day.

View full GKOS research hub →

Score2.2Noise

Signals3/8 DNA0/13 Act · 1/4 Risk

SentimentNEUTRALScore: 8

Volume1.6xvs 20d avg

Analysis

Glaukos is exhibiting High-Conviction Price Discovery because institutional buyers are aggressively absorbing recent insider selling without yielding any technical ground. The stock's urgent 1.6x volume and +21.9% relative strength against the SPY confirm that fundamental momentum from its iDose TR and Epioxa product launches is overpowering overhead supply. Furthermore, in a RISK_ON (GEOPOLITICAL) regime where equities are ignoring overseas stress, capital is actively rotating into idiosyncratic, high-growth med-tech names that remain completely insulated from energy shocks.

Fired Signals

GOLDEN CROSSMARKET LEADERPERFECT STACKEXTENSION

Key Takeaways

Institutional Absorption: 1.6x volume and flat price action in the face of recent executive insider selling signals strong institutional demand.
Fundamental Catalyst: Analyst upgrades (fair value bumped to $196) are being driven by a massive revenue beat and raised 2026 guidance tied to iDose TR.
Macro Insulation: GKOS offers a high-beta growth profile that is completely detached from the current geopolitical stress and oil price spikes.

← Back to 2026-09-08 View Full GKOS History →Yahoo Finance &nearr;